BMS eyes move to Kendall Square; Novartis faces Zometa jaw claims; U.K. watchdogs agree to rehash Ferring's cancer med Firmagon;

@FiercePharma: Top-read on FP Monday: Should deal-needy Pfizer target antibiotics specialist Cubist? Article | Follow @FiercePharma

@TracyStaton: ICYMI yesterday: @NovoNordisk CEO on the house that Victoza built and the future of diabetes R&D. Report | Follow @TracyStaton

@EricPFierce: Indian drugmaker, Marck Biosciences, ravaged by FDA warning letter for records kept on 'scratch paper.' Story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Reckitt Benckiser chief ahead of the consumer health curve, analysts say. Article | Follow @CarlyHFierce

> Bristol-Myers Squibb ($BMY) is eyeing a big move into office and lab space in Cambridge, MA, targeting 200,000 square feet in the Kendall Square area, a hotbed of drug development. Report

> The U.S. Sixth Circuit kicked Novartis ($NVS) back to trial court in a case over jaw injuries allegedly linked to its bone drugs Aredia and Zometa. Report

> U.K. cost-effectiveness gatekeepers agreed to reconsider Ferring Pharmaceuticals' prostate cancer treatment Firmagon (degarelix), previously rejected for routine use by the National Health Service. Report

> Indian drugmakers are facing more frequent bars against launching generic versions of patented drugs, with more than 10 so far this year, up from a half dozen for all of 2012. Report

Medical Device News

@FierceMedDev: Blood test for drug-resistant malaria strain shows promise. FierceDiagnostics story | Follow @FierceMedDev

@StacyALawrence: ICYMI yesterday: Abbott gets $20M from DoD to develop portable concussion test. Article | Follow @StacyALawrence

@VarunSaxena2: My photo was published in @indystar! George Will: Progressives as economic innocents. Story via IndyStar | Follow @VarunSaxena2

@EmilyWFierce: Medtronic sticks to its guns on Covidien and reports strongest quarterly U.S. sales growth in 5 years. More from Reuters | Follow @EmilyWFierce

> Leading U.S. hospital group target of external cyberattack. News

> Feds looking to fund clinical studies on cardiology, hip fracture and surgical mesh, among other topics. More

> Cheap, portable Dx device detects an array of medical and environmental conditions. Article

Biotech News

@FierceBiotech: Amgen successfully hits another PhIII goal line with kidney dialysis drug. Story | Follow @FierceBiotech

@JohnCFierce: On again: Novartis slashes ante, inks another Gamida Cell buyout pact in $635M leukemia deal. Article | Follow @JohnCFierce

@DamianFierce: If Zosano Pharma pulls off its IPO this week, it'll be the 52nd biotech to go public this year, per . | Follow @DamianFierce

@EmilyMFierce: Over-hyped headline, but excellent points here: You Are Not Nearly Scared Enough About Ebola. More | Follow @EmilyMFierce

> Novartis slashes ante, inks another Gamida Cell buyout pact in $635M leukemia deal. Story

> Lilly grabs a 'tentative' FDA OK for insulin treatment, but Sanofi still blocks its path. More

> Dermira pockets $51M to bankroll skin treatments. News

> Amgen successfully hits another PhIII goal line with kidney dialysis drug. Article

Biotech Research News

> Bacteria injection shrinks tumors in animals. Report

> Diabetes culprit may be a single enzyme. Story

> Researchers unveil lung-on-a-chip device. Article

> Ebola protein discovery could aid drug development. More

> Organovo 3-D printed liver tissue moves closer to market. Item

Pharma Manufacturing News

> FDA warning letter says Marck plant plagued by faked records and dead frogs. Report

> Sweden's Recipharm moves on Italy with $160M deal for Corvette. More

> Big Pharma stands back as little guys work on plant-based drugs and manufacturing. Report

> Sun Pharma recalls nearly 500,000 bottles of antibiotics. Story

> Sanofi shipping new malaria treatment manufactured from 'semisynthetic artemisinin.' Article

And Finally... Too many cancer screenings are given to elderly people likely to die within a decade, a study found. Report

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.